The Anderson Perspective

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

Goldman Sachs Alternatives acquires FGI Worldwide, a strategic move to penetrate the specialized SME financing and Insurtech markets with new capital.

With a new CEO known for scaling tech firms, Hivelocity is expanding its bare metal and GPU capacity to capture the booming AI infrastructure market.

The Ethical AI Governance Group expands to Europe, appointing new leadership and forging global alliances to move AI from experimentation to responsible adoption.

With $14M in new funding, Balcony is building 'digital rails' to modernize America's vulnerable property records, a move seen as a national security issue.

Discover why Moscato d'Asti is shedding its old image, as its low-alcohol charm and versatility win over a new wave of global wine drinkers.

With its new CCO, the AI health-tech firm aims to commercialize its patient-data platform, tackling billion-dollar delays in drug development.

After nearly ceasing operations, the 100-year-old American clockmaker is revived by West Michigan investors, charting a new course for a legacy brand.

Tapestry beats Q3 estimates with a 25% sales surge, driven by Coach's revival. But as Kate Spade sales fall, can the company balance its portfolio?

The payments firm beat revenue estimates and reaffirmed guidance, sparking a 15% stock rally and signaling resilience amid global economic headwinds.

Europe's top frozen food firm sees revenue and profits plummet in Q1, but new leadership vows a strategic reset to thaw out future growth prospects.

Rice University is massively expanding its faculty and student body while vowing to keep its intimate feel. Is "personalized scale" possible or a paradox?

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

The 'Git-R-Done' comedian will bring his heartland humor to a new clip show, part of a larger strategy by V10 Entertainment and CBS Media Ventures.

As FDA rules on peptides shift, a new AI platform aims to give doctors clarity, separating solid science from speculation in the booming longevity market.

Creatv Bio will present data at ASCO 2026 on its LifeTracDx® blood test, showcasing its potential to personalize cancer treatment through key pharma partnerships.

A new survey shows millions embrace permanent freelance careers, but this freedom comes with a hidden tax on their health, family, and future stability.

Germany's startups attracted €1.7B in Q1 2026, fueled by US investors and a massive bet on artificial intelligence, signaling a new era for its ecosystem.

Beyond its first blockbuster, CRISPR Therapeutics reveals a deep pipeline for autoimmune and liver diseases, backed by a strong Q1 balance sheet.

The news agency was honored for its deep-dive investigations into Meta's AI risks and the Trump administration's use of executive power for retribution.